Randomized controlled trials demonstrate the efficacy of arginine-enriched nutritional supplements (immunonutrition) in reducing complications after surgery. the effectiveness of preoperative immunonutrition has not been evaluated in a community setting.
D
espite advances in technique and perioperative care, approximately 20% to 25% of people undergoing elective colon resections develop infectious, anastomotic, or wound complications. [1] [2] [3] infections comprise the single most common cause of complications and are estimated to cost $10 billion annually. 4 surgical complications are related to a patient's nutritional status, and this effect may be exerted through several mechanisms. Preoperative malnutrition because of poor oral intake significantly increases the risk of adverse events after surgery and leads to increased length of stay. 5 another mechanism by which nutrition plays a role in surgical complications involves arginine, an amino acid that is found in nitrate-rich foods. there is a known depletion of arginine related to the stress of surgery. 6, 7 this acute arginine "deficiency" occurs because of inflammation and tissue injury and causes both altered nitric oxide synthesis and T-cell dysfunction. Both of these predispose patients to infection and impaired wound healing. [8] [9] [10] this acute deficiency of arginine is potentially modifiable by preoperative supplementation of arginine. a number of commercial products contain arginine. this group of products is known as immunonutrition and is marketed for the reduction of infection in surgical and critical care populations. immunonutrition reduced the incidence of infections, surgical complications, or length of stay in 39 studies randomly selecting more than 2600 patients, 11, 12 and 7 randomized controlled trials (RCts) have compared the use of preoperative immunonutrition with controls undergoing Gi surgery. a metaanalysis of these trials showed a near halving of infectious complications (relative risk (RR), 0.51; 95% Ci, 0.35-0.73) in patients receiving immune-enhancing nutrition preoperatively. 12 the mean length of stay was also shorter among patients who received immunonutrition in these studies (13.6 vs 15.3 days; p < 0.01).
Despite these encouraging findings, no study has examined the comparative effectiveness of immunonutrition use across varied clinical practices outside a clinical trial. ideally, an effectiveness assessment evaluates outcomes in a nonresearch center setting, including a variety of patients, disease states, and clinicians from both academic and community hospitals, and without the restrictive criteria of a trial. evidence of an intervention's effectiveness may strengthen the results from efficacy studies and addresses the question of generalizability to other populations and communities. the purpose of this study was to examine the effectiveness of immunonutrition after colorectal surgery as part of a statewide public health intervention conducted across surgeons' practices at rural community hospitals, urban secondary and tertiary hospitals, and a single academic medical center in Washington state.
MATERIALS AND METHODS
the surgical Care and outcomes assessment Program (sCoaP) is a quality-improvement collaborative of over 50 hospitals in Washington state that began in 2006. surgical Care and outcomes assessment Program hospitals include 6 critical access hospitals, numerous rural and urban secondary and tertiary medical centers, and a single quaternary referral center. strong for surgery (s4s) is a statewide public health campaign developed by investigators at the university of Washington's surgical outcomes Research Center (funded in part through the agency for healthcare Research and Quality, Grant R01hs020025) that focuses on the implementation of evidence-based practices to optimize patients' health before surgery. initiated in 2012, s4s engages with surgeons by using preoperative checklists that guide providers in promoting smoking cessation, ensuring preoperative medication reconciliation, and nutritional optimization before surgery. for patients undergoing elective Gi surgery, s4s promotes the routine use of immunonutrition before surgery. Surgeons participate voluntarily in S4S. Beginning in 2011, to measure the effectiveness of preoperative immunonutrition, sCoaP began prospectively recording the use of immunonutrition at all its member hospitals, many of which include surgeons who participate in s4s.
We conducted a prospective cohort study of all adult patients undergoing colorectal surgery in the sCoaP collaborative during the time period of interest. Patients were included in the study if they underwent surgery at one of the sCoaP hospitals between January 1, 2012, and June 30, 2015. To control for hospital-level factors, we only included patients from hospitals that administered immunonutrition to at least 10 patients during the study period (n = 7 hospitals). Patients were excluded from this study if they underwent an emergency surgery or if they had an urgent condition for which they would not qualify for preoperative immunonutrition (bowel obstruction, colon ischemia, perforation, Gi bleeding, or volvulus). Patients younger than 18 years were excluded. At all hospitals, trained abstractors examined charts to determine whether surgeons instructed the patient to take immunonutrition before surgery. Patients receiving immunonutrition were instructed to take the oral supplement (impact, 237ml; nestle usa inc, Glendale, Ca) by mouth 3 times daily for the 5 days before surgery. this regimen matched the prescribed course of immunonutrition in most clinical trials.
abstractors reviewed the medical record for demographic, laboratory, operative, and other clinical details, including outcomes, during the 30-day period following surgery. the primary outcome was any serious adverse events (saes) including infection (surgical site infection, abscess, urinary tract infection, and pneumonia), reoperation, anastomotic leak, and death. the secondary outcome was prolonged length of stay (Plos) as defined by any length of stay greater than 1.5 times the median length of stay in the final cohort. surgical Care and outcomes assessment Program variable definitions are available online (http://www.scoap.org).
Patient characteristics are summarized by frequencies (categorical variables) and means with standard deviation (continuous variables). to evaluate for differences between patients who did and did not receive immunonutrition, we performed a univariate analysis with χ 2 tests or Fisher exact tests (categorical variables) and 2-tailed unpaired student t tests (continuous variables).
Because of significant differences between patients who were recommended to receive immunonutrition and those patients who did not, we performed a one-to-one propensity score matching of the 2 groups. Based on a logistic regression model including all demographic and clinically relevant covariates including age, BMI, ASA class, indication, operation type, use of colostomy, and insurance type, we calculated a propensity score as the probability of receiving immunonutrition for each patient. there was a significant increase in the use of immunonutrition over time from the beginning to the end of the study, so the regression model for calculating propensity scores also controlled for the years in the study. Because of differences in surgeon and hospital practices, and the influence of other quality improvements such as enhanced recovery after surgery, there was concern that variation across hospitals might lead to bias and confounding in both the receipt of immunonutrition and outcomes. to account for these differences, patients receiving immunonutrition were only matched one-to-one with nontreated patients from their own hospital by using a nearest-neighbor and no replacement method. after matching within each hospital, effects of immunonutrition on primary and secondary outcomes were assessed by using an unadjusted generalized linear model with a binomial distribution and a log link.
all statistical analyses were performed using commercially available software (stata, version 14; stataCorp, College Station, TX; R-software, version 3.1.3). All statistical tests were considered significant if p ≤ 0.05. this study was exempted from institutional review board review by agreement of the Washington state institutional review board and university of Washington human subjects committee. all data used in this analysis were deidentified.
RESULTS
a total of 3375 patients (mean age 59.9 ± 15.2 years, 56% female) underwent elective colon (79%) or rectal (21%) surgery at 7 hospitals. a total of 642 patients (18.7%) were instructed by their surgeon to take immunonutrition before surgery. With each passing year in the study, patients were more likely to receive immunonutrition, 1.4% in 2012 vs 34.1% in 2015. Patients who received immunonutrition were less often female (52% vs 57%; p = 0.02), included more patients in the higher asa classes (iii-V, 44% vs 38%; p = 0.01), more commonly had diagnoses of cancer (60% vs 50%; p < 0.01) or IBD (14% vs 8%; p < 0.01), and more commonly required an ostomy (18% vs 14%; p = 0.02) (table 1). Prolonged length of stay (1.5 times the median length of stay) in the final matched cohort was any stay greater than 8 days.
the unadjusted rate of saes was 6.8% in the group receiving immunonutrition and 8.3% among those who did not receive treatment (p = 0.25). Prolonged length of stay was 13.8% in the immunonutrition group and 17.3% in the untreated group (p = 0.04). it was more common among patients with than without saes (73.4% vs 13.1%; p < 0.001). figure 1 shows the distribution of propensity scores between patients recommended to receive immunonutrition and patients who did not receive immunonutrition. four hundred eighty patients receiving immunonutrition were matched to 480 nontreated patients at their own hospitals. after matching, there were no significant differences in demographic or operative characteristics between patients in the treated and nontreated groups (table 2) .
after matching, the rate of saes was 7.1% in the group receiving immunonutrition and 9.4% in those who did not (RR, 0.76; 95% Ci, 0.49-1.16; p = 0.19). the relative risk of Plos was 23% lower among patients receiving immunonutrition (15.6%) compared with the untreated group (20.4%) (RR, 0.77; 95% Ci, 0.58-1.01; p = 0.05).
DISCUSSION
This study examined the effectiveness of preoperative immunonutrition among patients undergoing elective colorectal surgery. there was a 23% reduction in Plos associated with immunonutrition use. although nonsignificant, we found a 24% reduction in sae (infections, anastomotic leaks, reoperation, and death) among patients recommended to take immunonutrition that appeared to be related to the reduction in Plos. importantly, our estimate of reduced adverse events is similar in magnitude to that identified in a meta-analysis of randomized trials (33%). 12 For decades, researchers have explored the role of nutrients, including arginine, in the treatment of patients with inflammation after physical injury, including surgery, with the goal of identifying a modifiable target to improve outcomes. arginine has been proposed as one of those targets, in part, because of the several implicated roles it plays in mitigating the harmful effects of inflammation. arginine is a known substrate for immune cells, and arginine deficiency appears to lead to t-cell dysfunction in animal models. 6, 8, 10 arginine is also a precursor for polyamines and hydroxyproline, compounds involved in wound healing. in the early 2000s, arginine supplementation was found to reduce infectious complications in patients undergoing elective surgery, 11 although the exact mechanism for this effect is still under debate. Compounding the challenge of evaluating arginine is that many of the commercial preparations that include arginine also include omega-3 fatty acids, and these too may have an effect on surgical outcomes. 13 Numerous RCTs have examined the efficacy of different immune-enhancing diets in Gi surgery.
14,15 Drover et al 4 reviewed 33 studies randomly assigning patients to perioperative use of immunonutrition around the time of elective surgery. they reported a 39% reduction in infectious complications as well as significantly lower lengths of stay. notably, 18 of the 21 trials on Gi surgery were in patients undergoing upper Gi surgery. among trials of lower Gi surgery (n = 2) there were no differences in length of stay, but complication rates were lower in treated patients. Seven trials included use of immunonutrition exclusively in the preoperative period, and aggregated results showed a 43% reduction in infectious complications but no difference in length of stay. 16, 18, 30, 36, 37, 47, 48 a recent Cochrane review includes a meta-analysis of 6 trials of preoperative immunonutrition and reports a 33% reduction in total complications among patients receiving immunonutrition in Gi surgery. 12, 16, 18, 30, 36, 37, 48 Recent meta-analyses have brought into question the efficacy of immunonutrition, in part, because of differences in both timing of administration and comparison groups. 49, 50 hegazi et al 49 reviewed trials of preoperative immunonutrition and found a reduction in infectious complications (oR, 0.49; p < 0.01) compared with control patients receiving no supplementation. But when comparing preoperative immunonutrition with controls that did receive oral supplementation, the difference in infectious complications was not significant (oR, 0.71; p = 0.44). 16, 18, 30, 36, 37, 47, [51] [52] [53] [54] [55] [56] [57] [58] failure in this analysis to detect a difference in outcomes may No previous studies have examined the outcomes of immunonutrition outside a clinical trial, where compliance may be a challenge, and where there is more heterogeneity in clinical practice and patient characteristics. We found that the recommendation to take immunonutrition before surgery was associated with a reduced rate of Plos, and that Plos was related to saes. the relative risk reduction associated with immunonutrition was not statistically significant, but the direction of effect on sae (a lowering of 24%) was similar to many previous RCts. one explanation that may account for this was the relatively low rate of observed infectious complications in our study (7.1% vs 9.4% in patients not receiving immunonutrition) compared with previously reported studies. the review by Drover et al reported a 41% reduction in infectious complications among 28 trials reporting infections, but observed this effect with a much higher rate of adverse events (16.5% vs 27.7%; p < 0.0001). 4 Burden et al also reported significant reductions in infectious complications (14.2% vs 27%; p < 0.001) but with a similarly high level of events. 12 Based on a sample size estimation, a study designed to detect the risk reduction identified in our study (from 9% to 7%) would require enrollment of 2987 patients per arm. this suggests that our study may be underpowered to detect significant reductions in serious complication rates. this difference in adverse event rates may be due to the predominance of high-risk and upper Gi surgery in trials (esophagectomy, gastrectomy, and pancreaticoduodenectomy) compared with the relatively lower-risk colorectal resections included in this study. lower complication rates observed in this study also may be due to concurrent implementation of enhanced recovery after surgery protocols over the same period. We did observe a difference in rates of immunonutrition use between earlier and later years in this study, and the regression model used to calculate propensity scores adjusted for year to account for this observation.
there are several limitations to this study. in particular, confounding by indication may have occurred, meaning that patients who received the intervention are different in both measured and unmeasured factors from those who did not receive it. Propensity score matching allows for a comparison of patient groups that are more balanced in measured factors, allowing them to look more like populations from a randomized trial that are balanced through the randomization process. With the use of this approach, patient, clinical, and surgical factors were not significantly different between matched groups. the sCoaP database does not provide surgeon-specific data such as number of years in practice or fellowship training. However, by exclusively matching patients recommended to receive immunonutrition to nontreated patients from the same hospitals, we hoped to control for major differences in outcome that may be due to surgeon factors. Patients who received immunonutrition either paid for it themselves or were provided the supplement from the clinic or hospital free of charge. there is a possibility that patients with limited financial resources were unable to access immunonutrition. however, the rates of medicaid insurance among those who did and did not receive immunonutrition was similar (15.7% vs 14.1%). it is unclear whether patients who were advised to take immunonutrition actually complied with the recommendation, and if so, took all of the supplements. Rather, sCoaP abstractors identify whether the patients were instructed by their surgeon to take the supplement by reviewing the medical record. this may represent a conservative bias (eg, some patients who appear to have received the supplement did not in fact use it). this bias might be expected to minimize differences in outcomes between groups, and, if accounted for, might even accentuate the observed differences. it is also possible that, during the early phases of this study, the low rate of immunonutrition use was because the recommendation for receipt of the supplement was not documented consistently. this is also a bias that might be expected to minimize the observed difference between treatment and nontreatment. last, most patients who received immunonutrition were also part of the broader s4s initiative focused on improved glucose control, smoking cessation, and medicine reconciliation. although not controlling for these elements directly, after matching, we found no significant differences in perioperative hyperglycemia (10.8% vs 9.4%), cigarette smoking (27.9% vs 27.1%), or β-blocker continuation (95.9% vs 93.1%) between the groups who did and did not receive immunonutrition. 
CONCLUSION
the use of preoperative immunonutrition as part of the s4s public health campaign helped to improve surgical outcome and was associated with fewer patients requiring a Plos (≥8 days). this study supports the adoption of immune-enhancing nutrition before elective surgery as a way to reduce prolonged hospitalizations and improve the quality of surgical care. 
